Literature DB >> 18158945

Feasibility studies of 4'-[methyl-(11)C]thiothymidine as a tumor proliferation imaging agent in mice.

Jun Toyohara1, Maki Okada, Chie Toramatsu, Kazutoshi Suzuki, Toshiaki Irie.   

Abstract

This study reports on the radiosynthesis and feasibility studies of 4'-[methyl-(11)C]thiothymidine ([methyl-(11)C]S-dThd) as a tumor proliferation imaging agent. [Methyl-(11)C]S-dThd was synthesized by rapid methylation of corresponding 5-trimethylstannyl- or 5-tributylstannyl-precursor via a palladium-promoted Stille cross-coupling reaction with [(11)C]methyl iodide. The decay-corrected radiochemical yields of [methyl-(11)C]S-dThd synthesized by the corresponding 5-trimethylstannyl-precursor and 5-tributylstannyl-precursor based on [(11)C]CO(2) were 18.9% and 14.5%, respectively. The radiochemical purity of [methyl-(11)C]S-dThd was always greater than 99%. The specific activities of [methyl-(11)C]S-dThd synthesized by the corresponding 5-trimethylstannyl-precursor and 5-tributylstannyl-precursor were 47 GBq/mumol and 121 GBq/mumol, respectively, at the end of the synthesis. The total synthesis time was 30 min after the end of bombardment. The comparison between in vivo distribution of [methyl-(14)C]S-dThd and that of [methyl-(3)H]FLT showed that tracer uptake was comparable in nonproliferating tissues. In contrast, [methyl-(14)C]S-dThd showed significantly higher uptake in proliferating tissues than did [methyl-(3)H]FLT. [Methyl-(11)C]S-dThd uptake levels in five different tumor tissues were well correlated with the DNA synthesis levels determined by [2-(14)C]thymidine DNA incorporation. At 30 min after injection, plasma analysis found 95% of the activity in unmetabolized form. The microPET imaging of the C6 glioma xenograft showed significantly high uptake in the tumor and urinary bladder, followed by the intestine and marrow. Our results demonstrated that the tumor uptake of [methyl-(11)C]S-dThd was higher than that of [methyl-(3)H]FLT and was well correlated with the DNA synthesis level. Consequently, 4'-[methyl-(11)C]thiothymidine has promise for the imaging of tumor cell proliferation by positron emission tomography.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18158945     DOI: 10.1016/j.nucmedbio.2007.10.001

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  14 in total

1.  Quantifying initial cellular events of mouse radiation lymphomagenesis and its tumor prevention in vivo by positron emission tomography and magnetic resonance imaging.

Authors:  Sumitaka Hasegawa; Yukie Morokoshi; Atsushi B Tsuji; Toshiaki Kokubo; Ichio Aoki; Takako Furukawa; Ming-Rong Zhang; Tsuneo Saga
Journal:  Mol Oncol       Date:  2014-12-03       Impact factor: 6.603

Review 2.  Utilization of neural stem cell-derived models to study anesthesia-related toxicity and preventative approaches.

Authors:  Cheng Wang; Fang Liu; Tucker A Patterson; Merle G Paule; William Slikker
Journal:  Mol Neurobiol       Date:  2013-07-12       Impact factor: 5.590

3.  Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.

Authors:  Momoko Okasaki; Kazuo Kubota; Ryogo Minamimoto; Yoko Miyata; Miyako Morooka; Kimiteru Ito; Kiichi Ishiwata; Jun Toyohara; Tomio Inoue; Risen Hirai; Shotaro Hagiwara; Akiyoshi Miwa
Journal:  Ann Nucl Med       Date:  2014-11-25       Impact factor: 2.668

4.  In vitro analysis of transport and metabolism of 4'-thiothymidine in human tumor cells.

Authors:  David A Plotnik; Stephen Wu; Geoffrey R Linn; Franco Chi Tat Yip; Natacha Lou Comandante; Kenneth A Krohn; Jun Toyohara; Jeffrey L Schwartz
Journal:  Nucl Med Biol       Date:  2014-12-06       Impact factor: 2.408

5.  Comparison of 4'-[methyl-(11)C]thiothymidine ((11)C-4DST) and 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) PET/CT in human brain glioma imaging.

Authors:  Yasunori Toyota; Keisuke Miyake; Nobuyuki Kawai; Tetsuhiro Hatakeyama; Yuka Yamamoto; Jun Toyohara; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  EJNMMI Res       Date:  2015-03-05       Impact factor: 3.138

6.  Clinical value of PET/CT with carbon-11 4DST in the evaluation of malignant and benign lung tumors.

Authors:  Ryuichi Nishii; Tsuneo Saga; Hitomi Sudo; Takashi Togawa; Junpei Kuyama; Toshiaki Tani; Takamasa Maeda; Masato Kobayashi; Toshihiko Iizasa; Masato Shingyoji; Makiko Itami; Kazunori Kawamura; Hiroki Hashimoto; Kana Yamazaki; Kentaro Tamura; Tatsuya Higashi
Journal:  Ann Nucl Med       Date:  2021-01-02       Impact factor: 2.668

7.  Advanced pre-clinical research approaches and models to studying pediatric anesthetic neurotoxicity.

Authors:  Cheng Wang
Journal:  Front Neurol       Date:  2012-10-17       Impact factor: 4.003

8.  A novel (11)C-labeled thymidine analog, [(11)C]AZT, for tumor imaging by positron emission tomography.

Authors:  Tsuyoshi Tahara; Zhouen Zhang; Masahiro Ohno; Yukako Hirao; Nami Hosaka; Hisashi Doi; Masaaki Suzuki; Hirotaka Onoe
Journal:  EJNMMI Res       Date:  2015-09-04       Impact factor: 3.138

9.  A pilot study of 4'-[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer.

Authors:  Ryogo Minamimoto; Jun Toyohara; Hideyuki Ito; Ayako Seike; Yoko Miyata; Miyako Morooka; Momoko Okasaki; Kazuhiko Nakajima; Kimiteru Ito; Kiichi Ishiwata; Kazuo Kubota
Journal:  EJNMMI Res       Date:  2014-03-05       Impact factor: 3.138

Review 10.  Usefulness of positron emission tomographic studies for gliomas.

Authors:  Keisuke Miyake; Daisuke Ogawa; Masaki Okada; Tetsuhiro Hatakeyama; Takashi Tamiya
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-05-31       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.